Novel Inhibitors of Human Histone Deacetylase (HDAC) Identified by QSAR Modeling of Known Inhibitors, Virtual Screening, and Experimental Validation
暂无分享,去创建一个
Hao Tang | Xi-Ping Huang | Bryan L. Roth | Alexander Tropsha | Xiang S. Wang | Kyle V. Butler | Alan P. Kozikowski | Mira Jung | A. Tropsha | Xi-Ping Huang | B. Roth | Hao Tang | M. Jung | A. Kozikowski | X. Wang
[1] Igor V. Tetko,et al. Combinatorial QSAR Modeling of Chemical Toxicants Tested against Tetrahymena pyriformis , 2008, J. Chem. Inf. Model..
[2] Alexander Golbraikh,et al. Application of predictive QSAR models to database mining: identification and experimental validation of novel anticonvulsant compounds. , 2004, Journal of medicinal chemistry.
[3] Alexander Tropsha,et al. Novel Variable Selection Quantitative Structure-Property Relationship Approach Based on the k-Nearest-Neighbor Principle , 2000, J. Chem. Inf. Comput. Sci..
[4] T. Suzuki,et al. Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. , 1999, Journal of medicinal chemistry.
[5] A. Balaban. Highly discriminating distance-based topological index , 1982 .
[6] Yuka Kanno,et al. Interaction of Histone Acetylases and Deacetylases In Vivo , 2003, Molecular and Cellular Biology.
[7] M. Randic. Characterization of molecular branching , 1975 .
[8] R. Sternglanz,et al. The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[9] Alexander Golbraikh,et al. Differentiation of AmpC beta-lactamase binders vs. decoys using classification kNN QSAR modeling and application of the QSAR classifier to virtual screening , 2008, J. Comput. Aided Mol. Des..
[10] Yan-shen Guo,et al. Exploration of a binding mode of indole amide analogues as potent histone deacetylase inhibitors and 3D-QSAR analyses. , 2005, Bioorganic & medicinal chemistry.
[11] Silvio Massa,et al. Class II-selective histone deacetylase inhibitors. Part 2: alignment-independent GRIND 3-D QSAR, homology and docking studies. , 2008, European journal of medicinal chemistry.
[12] Manfred Jung,et al. Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. , 2002, Journal of medicinal chemistry.
[13] L. Gomez‐Paloma,et al. Chemistry and biology of chromatin remodeling agents: state of art and future perspectives of HDAC inhibitors. , 2006, Current medicinal chemistry.
[14] Kurt Hornik,et al. kernlab - An S4 Package for Kernel Methods in R , 2004 .
[15] K. Glaser,et al. Histone deacetylase inhibitors: the Abbott experience. , 2003, Current medicinal chemistry.
[16] Lemont B. Kier,et al. An index of electrotopological state for atoms in molecules , 1991 .
[17] Daniel Delorme,et al. Structurally simple trichostatin A-like straight chain hydroxamates as potent histone deacetylase inhibitors. , 2002, Journal of medicinal chemistry.
[18] A Tropsha,et al. Identification of the descriptor pharmacophores using variable selection QSAR: applications to database mining. , 2001, Current pharmaceutical design.
[19] J. Gasteiger,et al. ITERATIVE PARTIAL EQUALIZATION OF ORBITAL ELECTRONEGATIVITY – A RAPID ACCESS TO ATOMIC CHARGES , 1980 .
[20] Alexander Golbraikh,et al. Predictive QSAR modeling based on diversity sampling of experimental datasets for the training and test set selection , 2002, J. Comput. Aided Mol. Des..
[21] Carlos Jiménez,et al. Novel marine sponge derived amino acids 13. Additional psammaplin derivatives from Psammaplysilla purpurea , 1991 .
[22] H. Wiener. Structural determination of paraffin boiling points. , 1947, Journal of the American Chemical Society.
[23] A. Wolffe,et al. Chromatin remodeling: why it is important in cancer , 2001, Oncogene.
[24] O. Wiest,et al. Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases. , 2005, Journal of medicinal chemistry.
[25] Alexander Tropsha,et al. QSAR modeling of human serum protein binding with several modeling techniques utilizing structure-information representation. , 2006, Journal of medicinal chemistry.
[26] Silvio Massa,et al. 3-D QSAR Studies on Histone Deacetylase Inhibitors. A GOLPE/GRID Approach on Different Series of Compounds , 2006, J. Chem. Inf. Model..
[27] L. Ngo,et al. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[28] Vithal M Kulkarni,et al. 3D-QSAR of histone deacetylase inhibitors as anticancer agents by genetic function approximation. , 2006, Indian journal of biochemistry & biophysics.
[29] G Brosch,et al. Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation. , 1999, Journal of medicinal chemistry.
[30] J. Irwin,et al. ZINC ? A Free Database of Commercially Available Compounds for Virtual Screening. , 2005 .
[31] V. Kulkarni,et al. 3D-QSAR of histone deacetylase inhibitors: hydroxamate analogues. , 2006, Organic & biomolecular chemistry.
[32] J. R. Somoza,et al. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. , 2004, Structure.
[33] H. Wiener. Correlation of Heats of Isomerization, and Differences in Heats of Vaporization of Isomers, Among the Paraffin Hydrocarbons , 1947 .
[34] Alexander Golbraikh,et al. A Novel Automated Lazy Learning QSAR (ALL-QSAR) Approach: Method Development, Applications, and Virtual Screening of Chemical Databases Using Validated ALL-QSAR Models , 2006, J. Chem. Inf. Model..
[35] Ricky W Johnstone,et al. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? , 2003, Cancer cell.
[36] Minoru Yoshida,et al. [Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A]. , 1990, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.
[37] D. Faller,et al. A mechanistic approach to anticancer therapy: targeting the cell cycle with histone deacetylase inhibitors. , 2005, Current pharmaceutical design.
[38] Ivan V. Gregoretti,et al. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. , 2004, Journal of molecular biology.
[39] Alexander Golbraikh,et al. Predictive QSAR modeling workflow, model applicability domains, and virtual screening. , 2007, Current pharmaceutical design.
[40] Ricky W. Johnstone,et al. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer , 2002, Nature Reviews Drug Discovery.
[41] Asad Umar,et al. Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. , 2004, Journal of medicinal chemistry.
[42] R A Rifkind,et al. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[43] Bryan L. Roth,et al. Finding New Tricks For Old Drugs: An Efficient Route For Public-Sector Drug Discovery , 2005, Nature Reviews Drug Discovery.
[44] S. Schreiber,et al. Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs. , 1997, Current opinion in chemical biology.
[45] Michel Petitjean,et al. Applications of the radius-diameter diagram to the classification of topological and geometrical shapes of chemical compounds , 1992, J. Chem. Inf. Comput. Sci..
[46] Yong-Jun Jiang,et al. Identification of ligand features essential for HDACs inhibitors by pharmacophore modeling. , 2008, Journal of molecular graphics & modelling.
[47] Jessica E. Bolden,et al. Anticancer activities of histone deacetylase inhibitors , 2006, Nature Reviews Drug Discovery.
[48] Alexander Golbraikh,et al. Combinatorial QSAR Modeling of Specificity and Subtype Selectivity of Ligands Binding to Serotonin Receptors 5HT1E and 5HT1F. , 2008 .
[49] A. Kozikowski,et al. Chemistry, Biology, and QSAR Studies of Substituted Biaryl Hydroxamates and Mercaptoacetamides as HDAC Inhibitors—Nanomolar‐Potency Inhibitors of Pancreatic Cancer Cell Growth , 2008, ChemMedChem.
[50] M. Jung,et al. Chemistry and biology of mercaptoacetamides as novel histone deacetylase inhibitors. , 2005, Bioorganic & medicinal chemistry letters.
[51] A. Wolffe,et al. Histone Deacetylase--A Regulator of Transcription , 1996, Science.
[52] M Ohtani,et al. (2E)-5-[3-[(phenylsulfonyl)amino]phenyl]-pent-2-en-4-ynohydroxamic acid and its derivatives as novel and potent inhibitors of ras transformation. , 1996, Journal of medicinal chemistry.
[53] P. Marks,et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors , 1999, Nature.
[54] P. Jurs,et al. Development and use of charged partial surface area structural descriptors in computer-assisted quantitative structure-property relationship studies , 1990 .
[55] Bin Chen,et al. Functional differences in epigenetic modulators-superiority of mercaptoacetamide-based histone deacetylase inhibitors relative to hydroxamates in cortical neuron neuroprotection studies. , 2007, Journal of medicinal chemistry.
[56] Paul Helquist,et al. QSAR studies of PC-3 cell line inhibition activity of TSA and SAHA-like hydroxamic acids. , 2004, Bioorganic & medicinal chemistry letters.
[57] R. De Francesco,et al. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[58] Alexander Golbraikh,et al. Quantitative Structure–activity Relationship Analysis of Pyridinone HIV-1 Reverse Transcriptase Inhibitors using the k Nearest Neighbor Method and QSAR-based Database Mining , 2005, J. Comput. Aided Mol. Des..
[59] Lemont B. Kier,et al. An Electrotopological-State Index for Atoms in Molecules , 1990, Pharmaceutical Research.
[60] Alexander Tropsha,et al. Antitumor Agents 252. Application of validated QSAR models to database mining: discovery of novel tylophorine derivatives as potential anticancer agents , 2007, J. Comput. Aided Mol. Des..
[61] Alexander Tropsha,et al. Application of validated QSAR models of D1 dopaminergic antagonists for database mining. , 2005, Journal of medicinal chemistry.
[62] Alexander Golbraikh,et al. Rational selection of training and test sets for the development of validated QSAR models , 2003, J. Comput. Aided Mol. Des..
[63] A. Tropsha,et al. Beware of q 2 , 2002 .
[64] Alexander Golbraikh,et al. Quantitative structure-activity relationship analysis of functionalized amino acid anticonvulsant agents using k nearest neighbor and simulated annealing PLS methods. , 2002, Journal of medicinal chemistry.